View Older Stories View More Recent Stories

May 10, 2021 04:48PM Biogen (BIIB) and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
May 10, 2021 04:06PM Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
May 10, 2021 04:06PM Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
Apr 28, 2021 06:20PM Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
Apr 28, 2021 06:20PM Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
Apr 28, 2021 07:30AM Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
Apr 28, 2021 07:30AM Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
Apr 19, 2021 07:38PM 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Jo
Apr 19, 2021 07:34AM Biogen (BIIB) Advances Leading Research in Spinal Muscular Atrophy with New Data at AAN
Apr 19, 2021 07:30AM Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
Apr 19, 2021 07:30AM Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
Apr 16, 2021 07:30AM New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Apr 16, 2021 07:30AM New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
Apr 15, 2021 04:34PM Biogen (BIIB) Grows Presence in China with the Approval of TECFIDERA for Treatment of Relapsing Multiple Sclerosis
Apr 15, 2021 04:30PM Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
Apr 15, 2021 04:30PM Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
Apr 14, 2021 04:09PM Biogen (BIIB) to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22
Apr 14, 2021 04:06PM Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
Apr 14, 2021 04:06PM Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
Apr 12, 2021 07:01AM SAGE Therapeutics (SAGE), Biogen (BIIB) Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Apr 12, 2021 07:00AM Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Apr 9, 2021 04:31PM Biogen (BIIB) Announces Two New Nominees for Election to Board of Directors
Apr 9, 2021 04:30PM Biogen Announces Two New Nominees for Election to Board of Directors
Apr 9, 2021 04:30PM Biogen Announces Two New Nominees for Election to Board of Directors
Apr 8, 2021 07:02AM Biogen (BIIB), Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Apr 8, 2021 07:00AM Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Apr 8, 2021 07:00AM Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
Apr 7, 2021 07:31AM Biogen (BIIB) Announces EC Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI to Treat Relapsing-Remitting Multiple Sclerosis
Apr 7, 2021 07:30AM The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
Apr 7, 2021 07:30AM The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
Mar 4, 2021 07:48AM Biogen (BIIB) to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Mar 4, 2021 07:47AM Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Mar 4, 2021 07:47AM Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
Feb 24, 2021 07:30AM Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
Feb 24, 2021 07:30AM Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
Feb 11, 2021 07:30AM Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
Feb 11, 2021 07:30AM Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
Feb 1, 2021 07:33AM Biogen (BIIB) Reports FDA Approval of PLEGRIDY (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Feb 1, 2021 07:31AM Biogen (BIIB) Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Feb 1, 2021 07:30AM Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Feb 1, 2021 07:30AM Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
Jan 29, 2021 07:35AM Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab
Jan 29, 2021 07:30AM Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Jan 29, 2021 07:30AM Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
Jan 11, 2021 07:30AM Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Jan 11, 2021 07:30AM Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Jan 11, 2021 06:00AM Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases
Jan 8, 2021 07:31AM Biogen (BIIB) Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA in Patients Treated With Zolgensma
Jan 8, 2021 07:30AM Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Jan 8, 2021 07:30AM Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
View More Recent Stories View Older Stories